Farms.com Home   News

Forecast decline in US soybean production

Nov 14, 2024
By Farms.com

Lower yields reduce US and global soybean forecasts

The recent Crop Production report, the USDA has adjusted the US soybean yield for the 2024/25 season downward to 51.7 bushels per acre, a decrease from the previous forecast of 53.1 bushels per acre.

This reduction translates to a lower overall production estimate of 4.5 billion bushels, a cut of 120.7 million bushels from earlier projections.

This lowered yield expectation has several repercussions for the soybean market. Domestic soybean crush figures are revised down to 2.4 billion bushels, and soybean exports are now expected to be 1.8 billion bushels, reflecting the impact of decreased production and current sales figures.

The season-average price for soybeans in the US remains unchanged at $10.80 per bushel despite these adjustments.

Internationally, the forecast for global soybean production has been revised downward to 425.4 million metric tons, a decrease influenced by reduced output in the US and India.

Global soybean trade is looking up, thanks to increased exports from Brazil, Canada, and Benin, which help offset the reduction in US exports.

While the global soybean crush is anticipated to decrease slightly, this is somewhat balanced by higher crushing volumes in countries like Pakistan. 

Ending stocks globally for soybeans are projected at 131.7 million metric tons for the 2024/25 marketing year, down by 2.9 million metric tons from the previous forecast but still above the prior year, pointing to an evolving but still robust global supply chain.


Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.